Would you change systemic therapy for metastatic melanoma on BRAF/MEK targeted therapy with excellent extracranial response, but with CNS-only progression?

If a patient is on BRAF/MEK dual targeted therapy with excellent extracranial response, but with CNS progression, I would favor continuing the BRAF/MEK inhibitor therapy and considering SRS to CNS lesion(s). However, if the patient has not received prior combination IO, another option to consider wo...